ID Biomedical - Elephant Hunting?? (IDBEF) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ID Biomedical - Elephant Hunting?? (IDBEF)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ignite44 who wrote (1)	1/17/1999 2:17:00 AM
From: Kaiser Soza	Read Replies (1) of 27

Hi Thomas, Regarding your first question, it is my understanding that this test, with its accuracy, cost and time benefits is unique and there is no real competition. ID Biomedical has developed a system similar to PCR (polymerase chain reaction) which was sold by Cetus to Hoffman LaRoche for over $300 million about 10 years ago. This is the DNA based testing that was used to identify blood in the O.J. Simpson trial. ID's platform is CPT (cycling probe technology) which has a number of benefits over PCR. The ultimate market for this product was originally the rapid diagnosis of Tuberculosis. They can identify TB in a lab environment, but the test still needs work to be applicable for sputum samples etc. The company has used the technology as a rapid test device in areas that are not as tough to crack as the TB, where there would be a large market. I am not certain if the test relates to the regular staphylococcus but I will check on it and post when I find out. Regards, Kaiser....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next